Severe Raynaud's Phenomenon with Yohimbine Therapy for Erectile Dysfunction

Journal of Rheumatology

Volumn 30, Issue 11, 2003, Pages 2503-2505

  Johnson, Sindhu ^a   Iazzetta, John ^a   Dewar, Catharine ^a  

^a NONE

Author keywords

Crest; Impotence; Raynaud's; Sildenafil; Yohimbine

Indexed keywords

FELODIPINE; GLYCERYL TRINITRATE; SILDENAFIL; YOHIMBINE;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG MECHANISM; ERECTILE DYSFUNCTION; FAMILY HISTORY; HUMAN; HYPOTENSION; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SYNDROME CREST; TREATMENT OUTCOME;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; CREST SYNDROME; HUMANS; IMPOTENCE; MALE; RAYNAUD DISEASE; SEVERITY OF ILLNESS INDEX; YOHIMBINE;

EID: 0242440724     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol 1998;159:433-6.
2. Goldberg MR, Robertson D. Yohimbine: a pharmacological probe for study of the alpha-2 adrenoreceptor. Pharmacol Rev 1983;35:143-80.
3. Baum N. Treatment of impotence. 1. Nonsurgical methods. Postgrad Med 1987;81:133-6.
4. Raynaud M. De la gangrene symetrique des extremites. Paris: Universite de Paris; 1862.
5. Towheed T, Dewar C. A practical approach to Raynaud's syndrome. Medicine N Am 1996;19:56-60.
6. Sandler B, Aronson P. Yohimbine-induced cutaneous drug eruption, progressive renal failure, and lupus-like syndrome. Urology 1993;41:343-5.
7. Corbin JD, Francis SH, Webb DJ. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology 2002;60:4-11.
8. Kloner RA, Zusman RM. Cardiovascular effects of sildenafil citrate and recommendations for its use. Am J Cardiol 1999;84:11N-17N.
9. Freedman RR, Baer RP, Mayes MD. Blockade of vasospastic attacks by alpha-2 adrenergic but not alpha-1 adrenergic antagonists in idiopathic Raynaud's disease. Circulation 1995;92:1448-51.
10. Tam SW, Worcel M, Wyllie M. Yohimbine: a clinical review. Pharmacol Ther 2001;91:215-43.
11. Sturgill MG, Grasing KW, Rosen RC, et al. Yohimbine elimination in normal volunteers is characterized by both one- and two-compartment behavior. J Cardiovasc Pharmacol 1997;29:697-703.
12. Le Corre P, Dollo G, Chevanne F, Le Verge R. Biopharmaceutics and metabolism of yohimbine in humans. Eur J Pharm Sci 1999;9:79-84.
13. Flavahan NA, Flavahan S, Liu Q, et al. Increased alpha-2 adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 2000;43:1886-90.